Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 17/20 | 0.45 |
| ▸ | PGR | P06401 | 14/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961287 | 1.00 | NR3C1 (0.45) | NR3C1NR3C2PGRAR | |
| SCHEMBL4802007 | 1.00 | NR3C1 (0.45) | NR3C1NR3C2PGRAR | |
| SCHEMBL4796692 | 0.93 | NR3C1 (0.43) | NR3C1NR3C2PGRAR | |
| SCHEMBL3957013 | 0.93 | NR3C1 (0.43) | NR3C1NR3C2PGRAR | |
| SCHEMBL3957015 | 0.93 | NR3C1 (0.43) | NR3C1NR3C2PGRAR | |
| SCHEMBL3956995 | 0.88 | NR3C1 (0.46) | NR3C1NR3C2PGRAR | |
| SCHEMBL3956993 | 0.88 | NR3C1 (0.46) | NR3C1NR3C2PGRAR | |
| SCHEMBL4796789 | 0.88 | NR3C1 (0.46) | NR3C1NR3C2PGRAR | |
| SCHEMBL6073366 | 0.80 | NR3C1 (0.56) | NR3C1NR3C2PGR | |
| SCHEMBL5201951 | 0.80 | NR3C1 (0.56) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| EP-1844039-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | NR3C1 2604/4885NR3C2 1476/4885PGR 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.